12 citations
,
November 2024 in “Plants” This study found that the phytosterols β-sitosterol, stigmasterol, and campesterol have low-to-negligible inhibitory activity against steroidal 5α-reductase type 2 compared to the synthetic inhibitor dutasteride, with β-sitosterol showing the highest activity among the tested phytosterols.
3 citations
,
January 2022 in “Precision medicine and clinical omics” This study reports that using molecular docking methods, beta-sitosterol and stigmasterol from Serenoa repens were identified as potential natural inhibitors of the 5AR1 enzyme, which could serve as novel treatments for androgenetic alopecia based on their inhibitory action observed in a laboratory setting.
2 citations
,
May 2025 in “The Journal of Dermatology” This study reported that a large proportion of US adults with physician-diagnosed alopecia areata experience substantial emotional and mental health comorbidities and report significant stigma across all disease severities, yet few are receiving counseling or therapeutic intervention.
March 2025 in “Acta Dermato Venereologica” This cross-sectional survey found that individuals with alopecia areata and androgenetic alopecia perceived stigmatization and impaired quality of life, with greater stigma reported in German-speaking participants; factors like gender, age, and disease severity influenced stigmatization levels.
May 2026 in “Scientific Reports” This study explored the potential of stigmasterol as a treatment for androgenetic alopecia through various simulation techniques, finding promising interactions with key genes involved in hair loss, but further experimental validation is needed before clinical application.